key: cord-0738160-mrq5hxsn
authors: Sandal, Shaifali; Boyarsky, Brian J.; Massie, Allan; Chiang, Teresa Po‐Yu; Segev, Dorry L.; Cantarovich, Marcelo
title: Immunosuppression practices during the COVID‐19 pandemic: A multinational survey study of transplant programs
date: 2021-06-13
journal: Clin Transplant
DOI: 10.1111/ctr.14376
sha: 3e34105262446d5ca52e9767c977d2044f522226
doc_id: 738160
cord_uid: mrq5hxsn

During the COVID‐19 pandemic, there has been wide heterogeneity in the medical management of transplant recipients. We aimed to pragmatically capture immunosuppression practices globally following the early months of the pandemic. From June to September 2020, we surveyed 1267 physicians; 40.5% from 71 countries participated. Management decisions were made on a case‐by‐case basis by the majority (69.6%) of the programs. Overall, 76.8% performed ≥1 transplantation and many commented on avoiding high‐risk transplantations. For induction, 26.5% were less likely to give T‐cell depletion and 14.8% were more likely to give non‐depleting agents. These practices varied by program‐level factors more so than the COVID‐19 burden. In patients with mild, moderate and severe COVID‐19 symptoms 59.7%, 76.0%, and 79.5% decreased/stopped anti‐metabolites, 23.2%, 45.4%, and 68.2% decreased/stopped calcineurin inhibitors, and 25.7%, 43.9%, and 57.7% decreased/stopped mTOR inhibitors, respectively. Also, 2.1%, 30.6%, and 46.0% increased steroids in patients with mild, moderate, and severe COVID‐19 symptoms. For prevalent transplant recipients, some programs also reported decreasing/stopping steroids (1.8%), anti‐metabolites (10.3%), calcineurin inhibitors (4.1%), and mTOR inhibitors (5.5%). Transplant programs changed immunosuppression practices but also avoided high‐risk transplants and increased maintenance steroids. The long‐term ramifications of these practices remain to be seen as programs face the aftermath of the pandemic.

reported the mortality rate to be 17.1% in admitted COVID-19 patients, but 40.5% in studies reporting outcomes in patients with critical illness. 10 Despite the immense amount of literature on COVID-19 over the past few months, navigating the evidence and applying it to immunosuppressed transplant recipients is a daunting task. Current practice recommendations are limited to expert opinions, which are based on emerging, but low-quality evidence in transplantation. 11 Existing data are at risk of outcome reporting bias, as not every patient case is being reported, and the nature and direction of the outcomes may determine what is being reported. While no specific data from trials including transplant recipients with COVID-19 have been published so far, concerns have been raised on the off-label and potentially harmful use of targeted therapies. 12, 13 Several variabilities also exist in managing immunosuppression. In the United States, centers were less likely to administer T-cell depleting agents (TDA) for induction. 14 In terms of maintenance immunosuppression, depending on the patient's symptoms, a stepwise reduction in immunosuppression is recommended. 1, 12, [14] [15] [16] There is a dearth of literature in practices related to non-hospitalized transplant recipients with COVID-19 and prevalent transplant recipients.

While published literature is evolving from case reports to larger multi-center studies and international registries, 15 sharing of experience worldwide is being called upon to provide a foundation for clinical care. 17 Thus, the aim of our study was to pragmatically capture immunosuppression management practices during the early months of the pandemic.

From June to September 2020, we conducted a multinational survey of transplant programs during the COVID-19 pandemic and this manuscript reports the immunosuppression management practices.

This study was approved by the Research Ethics Board at the McGill University Health Centre.

The survey was designed using an iterative process by our team composed of transplant professionals and research methodologists. To do this, we conducted a thorough review of the COVID-19 literature reported by the Transplantation Society and the American Society of Transplantation. For methodological guidance on survey creation, we sought the works of Boynton, Gillham, and Oppenheim. [18] [19] [20] We ensured questions were clear, simple, and neutral. 21 We reviewed all items for relevance, redundancy, and wording. To minimize bias due to predisposition toward socially acceptable answers, that is, social acceptability bias, we formulated the questions to be as neutral as possible. 22 To reduce the risk of acquiescence bias, where applicable, the Likert scale was used. 23 Following modifications and multiple rounds of revisions, the final survey was created and then reviewed by the executive committee of the Transplantation Society. It was self-administered electronically using the Qualtrics XM platform in English and Mandarin. The survey was first pilot tested using 10 participants who represented four different countries of varied income level. Following this only minor modifications were made, thus these responses were included in the data analysis.

We recruited a convenience sample of transplant physicians who were identified as key informants in their programs using publicly available data (congress web pages, program websites) and with the help of regional organizations and individuals (see acknowledgements). We sought one individual per organ transplant program from various centers across the world to take the survey (one center can have up to five different transplant programs, hence, up to five participants from each program could be contacted). Our recruitment goal was 500 different individuals representing 500 different transplant programs. We identified and contacted 1339 physicians from 80 different countries; of these 209 physicians had directly reached out to us with interest in participating in our study. Of the 1267 that were eligible, 513 from 71 different countries completed the survey for a response rate of 40.5%. We also used quota sampling to ensure a heterogenous sample as outlined in Figure 1 . 24

New transplantation was one that was performed during the pandemic. Patients with mild COVID-19 symptoms were those more likely to be treated as an outpatient; patients with moderate COVID-19 symptoms were those more likely to be treated as an inpatient but not ICU; and patients with severe COVID-19 symptoms were those who needed care in the ICU. Cumulative COVID-19 incidence (CCI) was calculated from March 13 to July 15, 2020 using the Johns Hopkins COVID Map and supplemented using data reported at covidindia.org. 25, 26 For the United States, Canada, Australia, India, and China, CCI was calculated by states/provinces.

Survey questions pertained to selecting pre-specified options. A comment box was provided to describe other practices and a descriptive review of these comments was also conducted. The specific outcomes of interest (both descriptive and objective) are as follows:

We first asked participants whether their program performed any new transplants during the pandemic. If yes, we asked if any recipients were infected with SARS-CoV-2. We also asked them to describe their impression for the following short-term outcomes when compared with their program's norm: acute rejection, infections (excluding COVID), patient death, primary non-function, and delayed graft function (kidney only). Participants were also asked to rate the likelihood of their program giving COVID-19 prophylaxis to new transplant recipients on a scale of 1 to 5 (1 being unlikely and 5 being very likely).

For induction immunosuppression practices, we asked programs if they made changes to TDA, non-TDA, and steroids protocols. We then analyzed if four factors influenced the odds of making changes to these induction therapies: the CCI, baseline transplant volume, type of organ transplant, and patient age group. To capture maintenance immunosuppression practices, we presented questions segregated by four clinical situations (prevalent patients and those with mild, moderate, and severe COVID-19 symptoms). We asked participants to report their program practices for most patients with respect to steroids, anti-metabolite agents, calcineurin inhibitors, and mammalian target of rapamycin (mTOR) inhibitors.

Each transplant program, hence, each survey response was treated as a unit of analysis. A descriptive analysis was conducted for each question and associated comments. For the outcome of the likelihood of giving COVID-19 prophylaxis, Bartlett's test of homogeneity of variances was used to examine variances across survey responses.

Multinomial logistic regression was used to determine the association between the variables mentioned above and the odds of making changes to induction immunosuppression. The response "do not know" was excluded for this analysis and when analyzing by the type of organ, and those who picked multiple organs as their scope of practice were also excluded. All analysis was performed using Stata 16.0/MP for Windows, and a significance level using P < .05 was reported. Table 1 and the location of the program is illustrated in Figure S1 . Management decisions during the pandemic were made on a case-by-case basis by 69.6% of the programs or using a standard policy by 27.5% (1.8% picked other and 1.2% picked do not know). Some reported deferring management decisions to the infectious disease specialists.

Overall, 76.8% of the programs were able to perform ≥1 transplantation during the first few months of the pandemic. Most programs were unlikely to administer any COVID-19 prophylactic agents to new transplant recipients; the mean score (standard deviation) (Table S1A) . Most observed no change in five short-term outcomes when compared with the norm.

( Figure S2 ). Also, many reported avoiding high-risk transplants, such as ABO-incompatible transplantation (Table S1A, B).

Changes to induction immunosuppression practices were reported by many programs. For TDA, non-TDA, and steroids, 56.1%, 71.9%, and 87.7% reported no change, 26.5%, 2.3%, and 1.0% reported less likely to give, and 1.9%, 14.8%, and 8.8% reported more likely to give, respectively. The remaining responded do not know or do not use. Some commented on decreasing the dose of TDA administered for induction (Table S1B) .

In regression analysis, CCI was not associated with the odds of reporting changes to induction immunosuppression practices, be it less likely or more likely to give, with one exception. When compared with transplant programs in areas with low CCI, those from areas with high CCI had 45% lower odds of reporting "less likely to give TDA" (odds ratio [OR] = 0.55, 95% confidence interval [CI]: 0.32-0.95). Program-level factors, in particular baseline volume, seemed to influence induction practices, particularly with respect to TDA and non-TDA. When compared to programs with low baseline transplant volumes, those with moderate and high volumes had higher odds of reporting both "less likely to give TDA" (OR = 2.19, 95%CI:1.24-3.87 and OR = 3.65, 95%CI:2.00-6.69) and "more likely to give non-TDA" (OR = 2.35 95%CI:1. 15-4.80 and OR = 2.87 95%CI:1.35-6.09), respectively. Type of organ transplant program (kidney/pancreas versus liver/lung/heart) was also associated with less likely to give TDA and more likely to give non-TDA. Last, compared with adult programs, pediatric-only programs had 66% lower odds of reporting "less likely to give TDA" (OR = 0.34 95%CI:0.14-0.84) ( Table 2 ).

For prevalent transplant patients, the majority made no changes to steroids (95.3%), anti-metabolite agents (86.7%), calcineurin inhibitors (94.1%), and mTOR inhibitors (85.4%) ( Figure 2 ). Although some did report decreasing/stopping/tapering them: 1.8% for steroids, 10.3% for anti-metabolite agents, 4.1% for calcineurin inhibitors, and 5.5% for mTOR inhibitors. In patients with COVID-19, as shown in Figure 2 , the symptoms of the patient influenced practice. Across the spectrum of mild, moderate, and severe COVID-19 symptoms, the percentage of programs that reported decreasing or stopping these agents increased from 59.7%-76.0%-79.5% for anti-metabolite agents, from 23.2%-45.4%-68.2% for calcineurin inhibitors, and from 25.7%-43.9%-57.7% for mTOR inhibitors. For steroids, there was a parallel increase in dose instead, 2.1%-30.6%-46.0%. Some programs also reported switching agents, such as, from tacrolimus to cyclosporine or from mycophenolate to azathioprine (Table S1C ).

The majority of transplant programs (70.6%) reported seeing or treating transplant recipients with suspected or confirmed COVID-19 (31.00% saw <5, 16.2% saw 5-10, 13.5% saw 11-20, 6.4% saw 21-50, and 3.5% saw >50 cases). Figure 3 demonstrates the responses of only those who reported seeing at least one transplant recipient with COVID-19. From these responses, 94.2%, 90.6%, 87.8%, 69.3%, and 51.4% agreed or strongly agreed that baseline co-morbidities, severity of symptoms, recipient age, baseline graft function, and type of solid organ determined their patients' outcomes, respectively. For the latter two, many picked neutral or do not know. that recipients in the pandemic era were 47% less likely to receive TDA compared to their pre-pandemic counterparts. 14 We report that many transplant programs across the world are indeed making changes to induction immunosuppression practices. Also, the type of solid organ and baseline transplant volumes influenced these changes more so than the COVID-19 burden. Higher volume centers were less likely to give TDA and more likely to give non-TDA perhaps speaks to their experience in transplantation or was done to mitigate the risk associated with nosocomial COVID-19 transmission. Also, the COVID-19 burden (as defined by CCI) did not influence induction immunosuppression practices except in areas with high CCI where programs had 45% lower odds of reporting "less likely to give TDA." This is counterintuitive, to what one might expect and the reason for this is unclear. One of the main reasons to use TDA is to enable high immunologic risk transplants and to decrease the risk and severity of acute rejection. 27, 28 In our survey, 3.1% did observe higher acute rejection, but many also reported avoiding high-risk transplants. None of these numbers were large enough or granular enough to conduct a robust analysis. However, future work should focus on comparing pre-pandemic and post-pandemic graft and patient outcomes due to these variable practices.

In recipients with COVID-19, there is no agreement on how best to manage these patients. 1 Note: "Less likely" (/"more likely") indicates that a program reported less likely (more likely) to use the agent in question during the early months of the pandemic, when compared to before the pandemic. a calculated from March 13 to July 15, 2020 as reported by the Johns Hopkins COVID Map, supplemented by covidindia.org. Reported in person per million population (ppm) and divided into tertiles for the entire cohort. Low: <2031 ppm, Medium: 2032-5400 ppm, High: >5400 ppm b Volume was defined as conducting the following number of transplants/year: Low<20, moderate 20-100, high >100. "0" with no confidence interval indicates that zero respondents in this category gave this response.

graft loss. 29, 30 However, some programs reported increasing doses of steroids, which may have been done in parallel to decreasing other immunosuppression or as a treatment modality. This may offset the risks of rejection and graft loss, but the long-term ramifications of these practices remain to be seen.

Two notable findings merit further discussion. Kidney transplant programs may be more disproportionately affected by the pandemic. Given the alternative of dialysis and reliance on the ethical principle of nonmaleficence, many programs globally suspended kidney transplantation in the initial months. 31 We report that only 69% state. In fact, immunosuppression is thought to represent a "protective factor" for COVID-19, 36 and more recent studies are reporting that transplantation in itself does not seem to be a risk factor for inferior outcomes. 7 

Data sharing requests for de-identified data reported in this article, will be considered upon written request to the corresponding author for up to 36 months following publication of this work. Data will be available subject to a written proposal, approval by an independent review committee, and a signed data sharing agreement.

F I G U R E 3 Determinants of outcome in patients with COVID-19: Only participants from programs that saw or treated transplant recipients with suspected or confirmed COVID-19 were asked to rate their level of agreement

Global transplantation COVID report

Covid-19 and solid organ transplantation: a review article

Early experiences with COVID-19 testing in transplantation

COVID-19 in lung transplant recipients

COVID-19 in solid organ transplant: a multi-center cohort study

The immunocompromised transplant recipient and SARS-CoV-2 infection

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: a retrospective cohort

COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities

COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis

Summary of International recommendations for donation and transplantation programs during the Coronavirus Disease (COVID-19) pandemic

Solid organ transplantation in the era of COVID-19: lessons from the past six months

Antivirals for COVID-19 in solid organ transplant recipients

Early changes in kidney transplant immunosuppression regimens during the COVID-19 pandemic

COVID-19 and kidney transplantation: a systematic review

COVID-19 therapeutics for solid organ transplant recipients; 6 months into the pandemic: where are we now?

Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve

Selecting, designing, and developing your questionnaire

Questionnaire Design, Interviewing and Attitude Measurement. London; NY: Pinter Publishers

Developing a Questionnaire

Questionnaire Design, Interviewing and Attitude Measurement

Data Quality in Telephone and Face-To-Face Surveys: A Comparative Meta-Analysis

Mode of questionnaire administration can have serious effects on data quality

Coronavirus COVID-19 global cases by the center for systems science and engineering

Open repository of all COVIDIndia.org's historical data

Rabbit antithymocyte globulin versus basiliximab in renal transplantation

Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients

The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation

mycophenolate reduction, and graft loss in kidney transplant recipients

Ethical Issues in the COVID Era: Doing the Right Thing Depends on Location, Resources, and Disease Burden

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Obesity in patients with COVID-19: a systematic review and meta-analysis

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Immunosuppression drug-related and clinical manifestation of coronavirus disease 2019: a therapeutical hypothesis

Immunosuppression practices during the COVID-19 pandemic: A multinational survey study of transplant programs